RxDoctor Payments Data

Shabana Jamil, MD

Internal Medicine · Vestal, NYNPI 1518031848

Payments from drug & device makers

$466in general payments, 2019–2025

Across 29 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$353
  • Astellas Pharma US Inc$45
  • Novartis$26
  • Shire North American Group Inc$17
  • Novo Nordisk$13
  • GSK$11

What the payments were for

  • Food & beverage$466100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)21$353
Astellas Pharma US Inc3$45
Novartis2$26
Shire North American Group Inc1$17
Novo Nordisk1$13
GSK1$11

How this compares

$466 in reported general payments places this provider in the 60th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$69,959
Medicare patients
256
Services billed
842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide113$129,746
EliquisApixaban121$106,159
JanuviaSitagliptin Phosphate30$40,881
JardianceEmpagliflozin19$25,596
XareltoRivaroxaban24$24,333
TrulicityDulaglutide13$22,086
JanumetSitagliptin Phos/Metformin Hcl18$16,876
FarxigaDapagliflozin Propanediol13$14,404
Levothyroxine Sodium603$9,658
Atorvastatin Calcium711$8,023
VascepaIcosapent Ethyl11$7,500
Metoprolol Succinate346$7,143
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$6,571
BrilintaTicagrelor14$5,778
SynthroidLevothyroxine Sodium71$5,731

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$13$129,746113 claims
AbbVieSynthroid$353$5,73171 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Vestal

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →